generated HIV-1 Gp120-specific T cell-based Gp120-Texo vaccine by ConA-stimulated C57BL/6 (B6) mouse CD8+ T (ConA-T) cells with the uptake of pcDNAGp120-transfected B6 mouse DC line DC2.4 (DC2.4Gp120)-released exosomes and indicated that CD8+ Gp120-Texo vaccine resulted in protective and durable immunity against Gp120-expressing B16 melanoma in both wild-type C57BL/6 and transgenic HLA-A2 mice which may indicate a modern vaccine for the immunotherapy of immunocompromised patients with HIV-1 infection [103, 106]. The gene discussed is CD8A; the disease is melanoma.